Sheaff Brock Investment Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-11,500	Closed	-$43K	–	571
2018 Q2	$43K	Hold	11,500	–	–	﹤0.01%	528
2018 Q1	$47K	Hold	11,500	–	–	﹤0.01%	535
2017 Q4	$53K	Hold	11,500	–	–	0.01%	514
2017 Q3	$82K	Hold	11,500	–	–	0.01%	543
2017 Q2	$83K	Sell	11,500 -1,500	-12%	-$9.37K	0.01%	576
2017 Q1	$80K	Buy	13,000 +1,500	+13%	+$8.22K	0.01%	570
2016 Q4	$67K	Buy	11,500 +1,500	+15%	+$8.2K	0.01%	584
2016 Q3	$53K	Hold	10,000	–	–	0.01%	537
2016 Q2	$66K	Hold	10,000	–	–	0.01%	562
2016 Q1	$47K	Hold	10,000	–	–	0.01%	587
2015 Q4	$51K	Buy	+10,000	New	+$47.5K	0.01%	615

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PIMJS

PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sheaff Brock Investment Advisors's KERX Position: Q3 2018 in Review

Sheaff Brock Investment Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2018, closing a stake of 11,500 shares — an estimated $43K sold.

Sheaff Brock Investment Advisors first reported a position in KERX in Q4 2015 and held it in 11 quarters. The position peaked at $83K in Q2 2017. 123 funds tracked by Wall St. Rank hold KERX as of Q3 2018.

Sheaff Brock Investment Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
Sheaff Brock Investment Advisors sold 11,500 Keryx Biopharmaceuticals Inc shares in Q3 2018, an estimated $43K.
Sheaff Brock Investment Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q4 2015 and held it in 11 quarters.
Sheaff Brock Investment Advisors's Keryx Biopharmaceuticals Inc position peaked at $83K in Q2 2017.
123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2018.

Based on Sheaff Brock Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.